Compare CWBC & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWBC | IRWD |
|---|---|---|
| Founded | 1989 | 1998 |
| Country | United States | United States |
| Employees | 341 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 644.3M | 663.6M |
| IPO Year | N/A | 2009 |
| Metric | CWBC | IRWD |
|---|---|---|
| Price | $26.89 | $4.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $28.63 | $7.67 |
| AVG Volume (30 Days) | 578.3K | ★ 2.3M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $39.58 | $57.95 |
| Revenue Next Year | $17.64 | $4.39 |
| P/E Ratio | ★ $12.13 | $18.04 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $18.51 | $0.67 |
| 52 Week High | $27.73 | $5.78 |
| Indicator | CWBC | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 68.26 | 64.92 |
| Support Level | $23.38 | $3.08 |
| Resistance Level | N/A | $4.50 |
| Average True Range (ATR) | 0.65 | 0.22 |
| MACD | 0.13 | 0.08 |
| Stochastic Oscillator | 73.75 | 93.33 |
Community West Bancshares is a bank holding company whose principal business is to serve as the holding company for its wholly-owned subsidiary Community West Bank N.A. Through CWB, the company provides a variety of financial products and full-service Banking Centers within California's Greater Sacramento, San Joaquin Valley, and Central Coast regions, that provide Commercial Lending, Real Estate, Agribusiness, Private Banking, and Cash Management Departments. The company has one reportable segment: Banking operations. Loans and leases, investment securities, interest-bearing deposits and non-interest income provide the revenues of the banking operation.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.